Descrizione del progetto
Colpire il tumore dell’ovaio e della vescica con nanoparticelle avanzate
Le opzioni terapeutiche disponibili per il cancro sono limitate a causa della variabilità dei tumori fra i pazienti. Per affrontare questo problema, Cristal Therapeutics (CT) ha sviluppato nanoparticelle avanzate chiamate CriPec®, che hanno la capacità di colpire in modo più efficace siti tumorali specifici. In alcuni studi preclinici CT ha dimostrato le eccezionali prestazioni terapeutiche del suo prodotto di punta, CriPec® docetaxel, un approccio alla medicina di precisione. Questo metodo ha mostrato risultati promettenti nei pazienti, con una notevole riduzione della neutropenia e dell’alopecia comunemente associate alle terapie tradizionali. Il progetto INTACT, finanziato dall’UE, prevede l’esecuzione di studi clinici di fase II sul cancro dell’ovaio e della vescica per valutare l’efficacia terapeutica di CriPec® docetaxel, nonché l’inserimento nel prodotto di un tracciante PET (89Zr), che consentirà agli oncologi di visualizzare la biodistribuzione di CriPec® in tempo reale.
Obiettivo
Cristal Therapeutics (CT) develops the next generation of nanomedicines to treat cancer. Cancer remains one the leading causes of death worldwide, and current treatment options are insufficient, in part due to the tumour heterogeneity between patients. CT has developed state-of-the-art nanoparticles (CriPec®) to target a drug of choice more selectively to the tumour site(s). The superior therapeutic performance of this approach has already been demonstrated preclinically for CT’ lead product CriPec® docetaxel and a promising clinical phase I trial is finalizing, providing a significantly increased pharmacokinetic and safety profile. CT already observed activity in patients and much reduced neutropenia and alopecia.
In INTACT, CT will perform phase II clinical trials in ovarian and bladder cancer to evaluate the therapeutic efficacy of CriPec® docetaxel. Furthermore, CriPec® docetaxel will be decorated with a PET tracer (89Zr), which enables oncologists to visualize CriPec® biodistribution in real-time. Tumour uptake will be correlated with therapeutic responses and result in parameters for future patient selection.
This approach turns the drug into a personalized medicine whereby only those patients that exhibit enhanced tumour-targeting will be treated. This personalisation assures maximum efficacy in selected patients, avoids exposing patients to inappropriate drugs and adverse effects, and allows patients with limited tumour targeting to receive other more appropriate treatment.
CT will use INTACT to close the gap from lab to market and facilitate a licensing deal for CriPec® docetaxel, projected to generate revenues exceeding >€100M in 2024. More importantly, INTACT will validate the CriPec® nanomedicine platform, boost product development for other diseases through licensing deals, and provide a growth of 10FTE by 2022. Success in INTACT will truly launch Cristal Therapeutics’ business.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineoncologybladder cancer
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health scienceshealth sciencespersonalized medicine
- engineering and technologynanotechnologynano-materials
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEINST-2-2016-2017
Meccanismo di finanziamento
SME-2 - SME instrument phase 2Coordinatore
6229 EV MAASTRICHT
Paesi Bassi
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.